Edwards Lifesciences Corp (NYSE:EW) Shares Purchased by Two Sigma Advisers LP

Two Sigma Advisers LP lifted its holdings in Edwards Lifesciences Corp (NYSE:EW) by 488.0% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,871,609 shares of the medical research company’s stock after purchasing an additional 1,553,306 shares during the period. Two Sigma Advisers LP owned approximately 0.30% of Edwards Lifesciences worth $129,347,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. San Francisco Sentry Investment Group CA raised its stake in shares of Edwards Lifesciences by 536.2% during the second quarter. San Francisco Sentry Investment Group CA now owns 369 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 311 shares in the last quarter. Savior LLC increased its stake in Edwards Lifesciences by 243.6% in the 2nd quarter. Savior LLC now owns 378 shares of the medical research company’s stock worth $26,000 after purchasing an additional 268 shares in the last quarter. Gemmer Asset Management LLC increased its stake in Edwards Lifesciences by 205.6% in the 2nd quarter. Gemmer Asset Management LLC now owns 382 shares of the medical research company’s stock worth $26,000 after purchasing an additional 257 shares in the last quarter. Sun Life Financial INC increased its stake in Edwards Lifesciences by 206.6% in the 2nd quarter. Sun Life Financial INC now owns 374 shares of the medical research company’s stock worth $26,000 after purchasing an additional 252 shares in the last quarter. Finally, Procyon Private Wealth Partners LLC increased its stake in Edwards Lifesciences by 276.3% in the 1st quarter. Procyon Private Wealth Partners LLC now owns 143 shares of the medical research company’s stock worth $27,000 after purchasing an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 79.70% of the company’s stock.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 68,550 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $68.22, for a total value of $4,676,481.00. Following the sale, the chief executive officer now directly owns 309,770 shares in the company, valued at $21,132,509.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 26,700 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $69.51, for a total value of $1,855,917.00. Following the completion of the sale, the chief financial officer now owns 27,114 shares in the company, valued at $1,884,694.14. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 352,504 shares of company stock worth $26,493,197. 1.48% of the stock is currently owned by company insiders.

EW has been the topic of a number of analyst reports. Canaccord Genuity lifted their price target on Edwards Lifesciences from $86.00 to $89.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Morgan Stanley lifted their target price on Edwards Lifesciences from $83.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Raymond James lifted their target price on Edwards Lifesciences from $83.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. SVB Leerink lifted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Finally, Oppenheimer assumed coverage on Edwards Lifesciences in a research note on Monday, July 13th. They set a “buy” rating and a $93.00 target price on the stock. Two research analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $84.42.

Shares of EW traded up $0.57 on Wednesday, reaching $83.87. 1,989,754 shares of the stock traded hands, compared to its average volume of 3,835,366. The firm has a market cap of $52.15 billion, a price-to-earnings ratio of 72.09, a P/E/G ratio of 2.79 and a beta of 0.87. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.08 and a quick ratio of 2.24. Edwards Lifesciences Corp has a 12 month low of $51.51 and a 12 month high of $87.79. The stock’s 50-day moving average price is $80.46 and its 200-day moving average price is $81.97.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.19. The business had revenue of $925.00 million for the quarter, compared to analysts’ expectations of $782.90 million. Edwards Lifesciences had a return on equity of 29.11% and a net margin of 17.21%. As a group, equities research analysts forecast that Edwards Lifesciences Corp will post 1.86 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Recommended Story: Cost of Capital Explained

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.